Study S001868

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin

ClinicalTrials.gov record

Registration

Registration: NCT02205528
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 108
Start: 2014-08-18
Primary completion: 2015-09-15
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus Type 2
Interventions: DRUG:Liraglutide; DRUG:Metformin; DRUG:Placebo; DRUG:NNC0090-2746
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1189-5627

Registered primary outcomes

Change in HbA1c [Day 1; Week 8]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015700	The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Frias JP, Cell metabolism	2017	Randomized trial	PMID 28768173 DOI	registry reference RESULT:28768173